Claritas Rx Highlights Fragmentation in Rare Disease Patient Support
Event summary
- Everest Group released a white paper highlighting fragmentation in omnichannel patient engagement for rare and specialty disease markets.
- The report identifies data coordination, consent governance, and AI-assisted decisioning as critical gaps in current patient support programs.
- Claritas Rx emphasizes the need for identity clarity, consent portability, and shared journey visibility to enable effective omnichannel support.
- The white paper is available to Claritas Rx customers and partners, providing a framework for operationalizing omnichannel engagement.
The big picture
The white paper underscores a persistent challenge in life sciences: despite heavy investment in omnichannel patient engagement, programs often deliver fragmented experiences. This inefficiency leads to delays in therapy initiation, lower treatment persistence, and reduced patient trust. Claritas Rx positions itself as a solution provider by emphasizing the need for a data-first foundation and AI-driven coordination to streamline patient support.
What we're watching
- Data Coordination
- How Claritas Rx will address fragmented data and limited interoperability to improve patient journey visibility.
- Consent Governance
- Whether the industry can standardize consent capture and governance to enable cross-entity support.
- AI Adoption
- The pace at which AI-assisted decisioning will shift patient services from broad outreach to need-based support.